Patent Grant
11161882
This application relates generally to the identification, isolation, modification and expression of a cluster of genes sufficient to produce a bacteriocin, and more specifically, a Phage tail-like bacteriocin (PTLB) that specifically kills Listeria species, and methods to alter its bactericidal specificity, produce, and use the same.
Listeria is a genus of bacteria, which includes at least fifteen species. Listeria species are gram-positive bacilli that are facultative anaerobes (i.e., capable of surviving in the presence or absence of oxygen). The major human pathogen in the Listeria genus is L. monocytogenes, which can grow and reproduce inside the infected host's cells and is one of the most virulent food-borne pathogens. L. monocytogenes is usually the causative agent of the relatively rare bacterial disease, listeriosis. Listeriosis is a serious disease for humans caused by eating food contaminated with the bacteria. The disease affects primarily pregnant women, newborns, adults with weakened immune systems, and the elderly. The overt form of the disease has a mortality rate of about 20 percent. The two main clinical manifestations are sepsis and meningitis. Listeria ivanovii is a pathogen of mammals, specifically ruminants, and has rarely caused listeriosis in humans.
Several strains of Listeria sps (monocytogenes, innocua, ivanovii) have been shown upon induction of the SOS response to produce high molecular weight (HMW) bacteriocins or Phage tail-like bacteriocins (PTLBs) termed “monocins” (Zink et al., 1994). These particles are released into the medium upon lysis of the monocin producer cells and have been shown by spot plate assay to have bactericidal activity on other Listeria strains. Particle production was confirmed by electron microscopy. Monocins produced by different strains displayed different bactericidal spectra. The genetic locus encoding a monocin has not been identified. The sequence of a putative monocin lytic enzyme was erroneously described many years ago (Zink et al., 1995; see below).
The present invention relates to the identification, cloning, and expression of a genetic locus within a Listeria genome that as a cluster of genes encodes a Phage tail-like bacteriocin (PTLB), termed a monocin or listeriocin, interchangeably. The present invention also relates to modified monocins. Monocins contain a receptor binding protein (RBP) that directs the binding of the monocin to the bacterium that it kills.
Accordingly, in one aspect, there are provided isolated nucleic acid molecules encoding a non-natural monocin, wherein the nucleic acid molecule contains a first polynucleotide that encodes a monocin structural scaffold, and a second polynucleotide encoding a heterologous RBP, wherein the scaffold contains all structural proteins of a functional monocin except its corresponding natural RBP, and wherein the monocin has bactericidal specificity as determined by the heterologous RBP. In some embodiments, the scaffold encoded by the first polynucleotide is at least 80% identical to SEQ ID NOs: 7-16, amino acid sequences ORFs 130-139.
In another aspect, there are provided producer cell integration vectors containing the disclosed nucleic acid molecule encoding a monocin, wherein the nucleic acid molecule is operably linked to a heterologous inducible promoter. In some embodiments, the producer cell is Bacillus subtilis. B. subtilis does not naturally produce a monocin.
In still another aspect, there are provided nucleic acid molecules encoding a monocin, wherein the nucleic acid molecule contains a polynucleotide that encodes amino acid sequences that are at least 80% identical to SEQ ID NOs: 5-17 and a heterologous promoter inducible by a small molecule, wherein the monocin has bactericidal activity, and wherein the polynucleotide is operably linked to the heterologous promoter. In particular embodiments, the promoter is placed at approximately 11, 14, 17, 20, or 23 nucleotides upstream of the portion of the polynucleotide encoding SEQ ID NO: 5. In a further aspect, there are provided monocin producer cells containing the disclosed nucleic acid molecules encoding a monocin. In some embodiments, the monocin producer cell contains a first foreign polynucleotide that encodes amino acid sequences that are at least 80% identical to SEQ ID NOs: 7-16 and a second foreign polynucleotide encoding an RBP, wherein the first and second polynucleotides encode a monocin having bactericidal specificity as determined by the RBP. In yet another aspect, there are provided methods of producing a monocin, by exposing a monocin producer cell containing a nucleic acid molecule encoding a monocin, wherein the nucleic acid molecule is operably linked to a heterologous inducible promoter, to an inducing agent in a concentration effective to induce expression of the monocin via the inducible promoter, thereby producing the monocin. In some embodiments, the nucleic acid molecule encoding a monocin is integrated within the genome of the producer cell in order to generate a stable monocin producer cell. In another aspect, there are provided methods of killing a Listeria species, comprising contacting the Listeria species with an effective amount of a monocin of the disclosure, whereby the monocin binds and kills the Listeria species. In some embodiments, the contacting is with a surface contaminated with Listeria species. In one example, the contacting is at 2-10° C. In another aspect, there are provided methods of treating an infection of Listeria species in an animal comprising, administering to an animal in need thereof an amount of a monocin of the disclosure, or a monocin producer cell of the disclosure in an amount sufficient to produce a bactericidal amount of the monocin, thereby treating the Listeria infection or colonization.
The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
The present invention is based on the identification, cloning, and expression of a genetic locus within a Listeria genome that encodes a Phage tail-like bacteriocin (PTLB), termed a monocin or listeriocin. Also provided are modified or non-natural monocins, such as those that have been engineered to have altered bactericidal specificity. Accordingly, provided herein are nucleic acid molecules encoding natural or non-natural monocins, integration vector constructs containing such nucleic acids operably linked to a heterologous promoter, producer cells that do not naturally produce monocins but containing such nucleic acid molecules or vectors, the encoded monocins, as well as methods of making and using such monocins.
As used interchangeably herein, the terms “Phage tail-like bacteriocin” (PTLB) and high molecular weight (HMW) bacteriocin may include, F-type bacteriocins (FTBs) and R-type bacteriocins (RTBs). For example, a monocin is a PTLB. The present inventors previously posited that monocins as contemplated herein have the structures of (RTBs), see U.S. Provisional Application No. 62/076,691, but as described herein, more closely resemble FTBs. A PTLB may be natural or non-natural, that is it exists in nature or does not exist in nature, respectively.
The terms “monocin” and “listeriocin” are used interchangeably herein, and refer to a PTLB isolated from or derived from a Listeria species. Monocins disclosed herein are complex molecules comprising multiple protein, or polypeptide, subunits and distantly resemble the tail structures of bacteriophages. In naturally occurring monocins the subunit structures are encoded by a genetic locus present within the bacterial genome such as that of L. monocytogenes, L. ivanovii, or L. innocua, and form monocins to serve as natural defenses against other bacteria. Monocins may be natural or non-natural.
A functional monocin contains a structural scaffold and an RBP (see
The RBP consists of an amino terminal portion that provides attachment (termed the “baseplate attachment region” or BPAR) to the rest of the monocin structural scaffold and a carboxy terminal portion that provides a receptor binding domain (RBD) that is the targeting motif of the RBP. In some embodiments, the BPAR is natural to the structural scaffold. In other embodiments the BPAR is highly homologous to the BPAR native to the structural scaffold. In particular embodiments, the BPAR is at least 80% identical to the BPAR native to the structural scaffold. In particular embodiments, the BPAR includes only the amino terminal 20 to 60 amino acids of ORF 140 (see
“Natural monocins” as used herein refer to those monocins that exist in nature, and include native particles obtained from Listeria, as well as particles obtained through expression of a natural monocin gene cluster in a monocin producer cell that does not in nature produce a monocin (see
“Non-natural monocins” as used herein refer to those monocins that do not exist in nature (see
Accordingly, there are provided nucleic acid molecules encoding a non-natural monocin, wherein the nucleic acid molecule includes a first polynucleotide that encodes all structural proteins of a functional monocin except a corresponding natural RBP, wherein the nucleic acid molecule further includes a heterologous second polynucleotide sequence encoding the heterologous RBP, and wherein the non-natural monocin has bactericidal specificity as determined by the heterologous RBP. In particular embodiments, the structural proteins encoded by the first polynucleotide correspond to ORFs 130-139 of a monocin genetic locus. In one example, the structural proteins are SEQ ID NOs: 7-16.
In particular embodiments, a non-natural monocin may include an RBP fusion. In one such example, the non-natural monocin contains a structural scaffold and an RBP fusion consisting of the BPAR from the corresponding natural RBP and a heterologous RBD. In some examples, the BPAR includes amino acid positions 1-40 of the natural RBP. To make a complete non-natural monocin molecule, the RBP fusion is attached to the structural scaffold, whereby the heterologous RBD determines the bactericidal spectrum of the resulting non-natural monocin. In examples where the non-natural monocin contains a heterologous RBP which is an RBP fusion, the nucleic acid molecule encoding the scaffold and the heterologous RBP is engineered so that the resulting monocin will contain a heterologous RBP consisting of amino acids at positions approximately 1-40 of the natural BPAR fused to the carboxy terminal portion of a heterologous RBD (see
As used herein, a “nucleic acid” or a “nucleic acid molecule” typically refers to deoxyribonucleotide or ribonucleotide polymers (pure or mixed) in single- or double-stranded form. The term may encompass nucleic acids containing nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, which have similar binding, structural, or functional properties as the reference nucleic acid, and which are processed in a manner similar to the reference nucleotides. Examples of such analogs include, without limitation, phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, 2-0-methyl ribonucleotides, and peptide-nucleic acids (PNAs). The term nucleic acid may, in some contexts, be used interchangeably with gene, cDNA, mRNA, oligonucleotide, and polynucleotide.
A particular nucleic acid sequence also encompasses conservatively modified variants thereof (such as degenerate codon substitutions) and complementary sequences, as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third (“wobble”) position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues. Thus, a nucleic acid sequence encoding a protein sequence disclosed herein also encompasses modified variants thereof as described herein. The terms “polypeptide”, “peptide”, and “protein” are typically used interchangeably herein to refer to a polymer of amino acid residues. Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission.
The term “segment” as used herein in reference to an amino acid sequence refers to a contiguous sequence of amino acids that may be 10, 12, 15, 20, 25, 50, or 100 amino acid residues in length. As used herein, the term “heterologous,” when used with reference to portions of a protein or nucleic acid sequence, indicates that the sequence comprises two or more subsequences that are not usually found in nature in the same relationship to each other. In one example, the heterologous sequences are from different species of bacteria. In another example, heterologous sequences are from different strains of the same species of bacteria. In one aspect, the heterologous sequences are from different strains of L. monocytogenes. In another aspect the heterologous sequences are from a bacterium and a bacteriophage or prophage, or from a bacterium and a synthetic, non-natural sequence of DNA.
The heterologous RBP may be comprised of an RBD obtained from another strain of L. monocytogenes, another species of Listeria, or a genus of bacteria other than the species and strain of the bacteria from which the scaffold was derived. In some embodiments, the species of Listeria include L. fleischmannii, L. grayi, L. innocua, L. ivanovii, L. marthii, L. rocourtiae, L. seeligeri, L. weihenstephanensis and L. welshimeri. In other embodiments, the genus of bacteria is selected from Clostridium, Staphylococcus, Streptococcus, Bacillus, Enterococcus, Propionibacterium. In some embodiments, the heterologous RBD is from a L. monocytogenes genome, a bacteriophage, a prophage insertion or a prophage remnant that is contained within a Listeria genome. A “prophage remnant” or prophage element or portion, refers to a sequence that encodes only a portion of a phage or discrete phage protein(s), rather than a full phage structure. Thus, in some embodiments, a prophage remnant may include, for example, sequence encoding an RBD and other structural proteins. In certain embodiments, the RBD is of a prophage or prophage remnant from the genome of a gram positive bacterium or an RBD of a bacteriophage that infects a gram positive bacterium. In one example, the gram positive bacterium is a species of Clostridium, Staphylococcus, Streptococcus, Bacillus, Enterococcus, or Propionibacterium. In some embodiments, the natural RBP of a natural monocin may be replaced with a modified form of a native RBP. A “native RBP” refers to a RBP having an amino acid sequence that is identical to a RBP isolated or cloned from another strain of L. monocytogenes or from a bacteriophage that infects L. monocytogenes or from another genus or species of bacteria or from a bacteriophage. Exemplary native RBP from L. monocytogenes include SEQ ID NOs: 17 and 26, from strains 35152 and F6854, respectively, and an exemplary native RBP from L. innocua includes SEQ ID NO: 27 from strain 33090. In some embodiments, a modified RBP includes a change in the amino acid sequence of the RBP relative to a native RBP. Non-limiting examples of a change in amino acid sequence include substitution, insertion (or addition), or deletion of one or more amino acids that modifies the binding or stability properties of the RBP.
In particular embodiments, the modified form of a native RBP also results in a monocin having a heterologous RBP and bactericidal spectrum that is different from a monocin containing the corresponding unmodified or native RBP. In particular embodiments, the modified form is at least 80% identical to the native RBP. In other embodiments, the RBP has an amino acid sequence that is at least 85%, 88%, 89%, 90%, 95%, 96%, 97%, 98%, or even 99% identical to a polypeptide selected from the group consisting of SEQ ID NOs: 17, 26, 27 and the modified RBP results in a monocin having a bactericidal spectrum that is different from a monocin having the corresponding unmodified or native RBP.
Also provided are variant monocins. Variant monocins include those monocins having an amino acid sequence that is at least 80% identical to a polypeptide containing ORFs 130-139 (SEQ ID NOs: 7-16), or ORFs 130-140 (SEQ ID NOs: 7-17). In other embodiments, the variant monocin has an amino acid sequence that is at least 85%, 88%, 89%, 90%, 95%, 96%, 97%, 98%, or even 99% identical to a polypeptide containing ORFs 130-139, or ORFs 130-140.
Also provided are vectors or expression constructs containing a nucleic acid molecule encoding a monocin. In some embodiments, the nucleic acid molecule is operably linked to a heterologous inducible promoter in the vector or expression construct. In particular embodiments, the heterologous promoter is a small molecule induced promoter. Examples of such small molecule induced promoters include PLAC (lactose, IPTG), PTAC (IPTG), PBAD (arabinose), and PXYL (Xylose). In particular embodiments, the promoter is placed at approximately 17 nucleotides upstream of a polynucleotide encoding ORF 128 (SEQ ID NO: 5) of the monocin.
In other embodiments, the vector or expression construct may include one or more regulatory proteins encoded by a monocin genetic locus or gene cluster. In particular embodiments, the one or more regulatory proteins are encoded by an ORF selected from the group consisting of ORFs 125, 126, 127, 128, and 129 (SEQ ID NOs: 2-6, respectively). In one example, the one or more regulatory proteins are encoded by an ORF selected from the group consisting of SEQ ID NOs: 2-6.
A monocin of the invention may be cold active, that is, it has bactericidal activity in cold temperatures, such as 2-10° C.
An additional property common to the monocins disclosed herein is that they do not contain nucleic acid and thus, are replication deficient such that they cannot reproduce themselves after or during the killing of a target bacterium, as can many bacteriophages. They are purely proteins, not organisms or viruses.
A “target bacterium” or “target bacteria” refers to a bacterium or bacteria that are bound by a monocin of the disclosure and/or whose growth, survival, or replication is inhibited thereby. In some embodiments, the target bacterium is from the genus Listeria. In some embodiments, the target bacterium is from a species of Listeria selected from the group consisting of L. monocytogenes, L. innocua, and L. ivanovii. In particular embodiments, the bacterium is Listeria monocytogenes. In one aspect, more than one strain of L. monocytogenes is targeted. Exemplary strains of Listeria monocytogenes include, but are not limited to, strain 15313 (serovar 1/2a), strain 19111 (serovar 1/2a), strain 35152 (serovar 1/2a), strain DD1144 (serovar 1/2a), strain DD1145 (serovar 1/2a), strain DD1152 (serovar 1/2a), strain DD1299 (serovar 1/2a), strain DD1313 (serovar 4b), strain DD1294 (serovar 4b), strain DP-L4056 (serovar (1/2a), strain DP-L3633 (serovar 1/2a), strain DP-L3293 (serovar 1/2c), strain DP-L3817 (serovar 1/2a), strain DP-L1171 (serovar 1/2b), strain DP-L185 (serovar 4b), strain DP-L186 (serovar 4b), strain DP-L188 (serovar 3), strain DP-L1173 (serovar 4b), strain DP-L1174 (serovar 4b), strain DP-L1168 (serovar 4b), strain DP-L1169 (serovar 4b), strain 23074 (serovar 4b), and Listeria ivanovii strain 19119 (serovar 5). In some embodiments, the target bacterium is from the genus Clostridum, Staphylococcus, Streptococcus, Bacillus, Enterococcus, or Propionibacterium. The term “growth inhibition” or variations thereof refers to the slowing or stopping of the rate of a bacterial cell's division or cessation of bacterial cell division, or to the death of the bacterium or bacteria.
Virulence factors are those molecules that contribute to the pathogenicity of an organism but not necessarily its general viability. Upon the loss of a virulence factor the organism is less pathogenic to a host but not necessarily less viable in culture. Virulence factors may have any one of numerous functions, for example, regulating gene expression, providing adhesion or mobility, providing a toxin, injecting a toxin, pumping out antibiotic agents, or forming protective coatings including biofilms.
Fitness factors are those molecules that contribute to the organism's general viability, growth rate or competitiveness in its environment. Upon the loss of a fitness factor, the organism is less viable or competitive and because of this compromise, indirectly less pathogenic. Fitness factors may also possess any one of numerous functions, for example, acquiring nutrients, ions or water, forming components or protectants of cell membranes or cell walls, replicating, repairing or mutagenizing nucleic acids, providing defense from or offense towards environmental or competitive insults.
Monocins targeting surface accessible virulence or fitness factors (e.g., Internalins on the surfaces of Listeria species and S-layer proteins, prevalent on many bacteria, the Clostridium species, for example) offer an attractive means of forcing such pathogens to compromise their virulence or fitness if they emerge as resistant to the monocin.
In additional embodiments, a monocin as provided herein is used to treat food or food storage areas contaminated with target bacteria. In particular embodiments, the monocin is cold stable, cold active, and is used to treat bacterial contamination of refrigerated food or refrigerated storage areas. Accordingly, there are provided methods of killing Listeria monocytogenes by contacting the L. monocytogenes with an effective amount of a monocin, whereby the monocin binds and kills the L. monocytogenes. In some embodiments, the contacting is in an animal and a bactericidal amount of the monocin is administered to the animal. In other embodiments, the contacting is with a surface contaminated with L. monocytogenes. In certain embodiments, the contacting is in the cold, for example at 2-10° C.
Also provided, are methods of treating an infection of L. monocytogenes in an animal by administering to an animal in need thereof an amount of a monocin, or a monocin producer cell to produce a bactericidal amount of the bacteriocin, thereby treating the infection.
As described herein, an anti-bacterial monocin may be used to inhibit growth, survival, or replication of a particular bacterium. The bacterium may be a pathogenic or environmentally deleterious strain, or may be treated in a prophylactic manner. A pathogenic microorganism generally causes disease, sometimes only in particular circumstances.
An engineered monocin of the disclosure may be administered to any subject afflicted with, diagnosed as afflicted with, or suspected of being afflicted with, an infection, colonized by, or contamination by bacteria susceptible to the monocin. Non-limiting examples of such a subject include animal (mammalian, reptilian, amphibian, avian, and fish) species as well as insects, plants and fungi. Representative, and non-limiting, examples of mammalian species include humans; non-human primates; agriculturally relevant species such as cattle, pigs, goats, and sheep; rodents, such as mice and rats; mammals for companionship, display, or show, such as dogs, cats, guinea pigs, rabbits, and horses; and mammals for work, such as dogs and horses. Representative, and non-limiting, examples of avian species include chickens, ducks, geese, and birds for companionship or show, such as parrots and parakeets. An animal subject treated with an engineered monocin of the disclosure may also be a quadruped, a biped, an aquatic animal, a vertebrate, or an invertebrate, including insects.
In some embodiments, the subject in need to be treated is a human child or fetus or other young animal which has yet to reach maturity. Thus the disclosure includes the treatment of pediatric or obstetric conditions comprising infection with bacteria or other microorganism susceptible to a monocin of the disclosure.
In some embodiments, there are provided compositions of more than one non-natural monocin, wherein the non-natural monocins have differing bactericidal spectra. In other embodiments, there are provided compositions of one or more non-natural monocins and one or more natural monocins, wherein the monocins have differing bactericidal spectra.
In some embodiments, monocins, combinations of monocins, or monocin producer cells capable of producing monocins are formulated with a “pharmaceutically acceptable” excipient, enteric coating or carrier. Such a component is one that is suitable for use with humans, animals, and/or plants without undue adverse side effects. Non-limiting examples of adverse side effects include toxicity, irritation, and/or allergic response. The excipient or carrier is typically one that is commensurate with a reasonable benefit/risk ratio. Non-limiting pharmaceutically suitable carriers include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples include, but are not limited to, standard pharmaceutical excipients such as a phosphate buffered saline solution, bicarbonate solution, water, emulsions such as oil/water emulsion, and various types of wetting agents. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyloleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like.
Additional formulations and pharmaceutical compositions disclosed herein comprise an isolated monocin specific for a bacterial pathogen; a mixture of two, three, five, ten, or twenty or more different monocins or producer cells capable of producing monocins that target the same bacterial pathogen; and a mixture of two, three, five, ten, or twenty or more that target different bacterial pathogens or different strains of the same bacterial pathogen.
Optionally, a composition comprising a monocin or producer cell of the disclosure may also be spray dried or lyophilized using means well known in the art. Subsequent reconstitution and use may be practiced as known in the field.
A monocin is typically used in an amount or concentration that is “safe and effective”, which refers to a quantity that is sufficient to produce a desired therapeutic or prophylactic response without undue adverse side effects like those described above. A monocin may also be used in an amount or concentration that is “therapeutically effective”, which refers to an amount effective to yield a desired therapeutic response, such as, but not limited to, an amount effective to slow the rate of bacterial cell division, or to cause cessation of bacterial cell division, or to cause death or decrease rate of population growth of the target bacteria. The safe and effective amount or therapeutically or prophylactically effective amount will vary with various factors but may be readily determined by the skilled practitioner without undue experimentation. Non-limiting examples of factors include the particular condition being treated, the physical condition of the subject, the type of subject being treated, the duration of the treatment, the nature of concurrent therapy (if any), and the specific formulations employed.
The terms “producer cell” and “monocin producer cell” are used interchangeably herein and refer to a cell that is capable of producing or expressing a monocin-encoding nucleic acid molecule, and which does not naturally contain such a nucleic acid molecule. The producer cell may be capable of surviving and growing in the presence of oxygen and is transformed with a vector containing a nucleic acid molecule encoding the monocin, which may be integrated into the chromosome of the producer cell or may be episomal. The producer cell may be a gram positive bacterium. In certain embodiments, the producer cell may be a bacterium from the genus Bacillus, Lactobacillus, Listeria, or Lactococcus.
In some embodiments, the bacterium is a species from the genus Bacillus selected from the group consisting of subtilis, amyloliquefaciens, and megaterium. In one aspect, the bacterium is Bacillus subtilis. In a particular aspect, the producer cell is a B. subtilis strain that lacks the PBSX gene cluster SpoA, Flag, etc. In other embodiments, the bacterium is a species from the genus Lactobacillus selected from the group consisting of acidophilus, casei, and bulgaricus. In another particular embodiment the producer cell is a species of Listeria other than monocytogenes capable of producing or expressing a monocin-encoding nucleic acid molecule and which does not naturally contain such a nucleic acid molecule. In some embodiments, a producer cell contains a first foreign polynucleotide that encodes an amino acid sequence that is at least 80% identical to SEQ ID NOs: 7-16 and a second foreign polynucleotide encoding a heterologous RBP, wherein the first and second polynucleotides encode a monocin having bactericidal specificity as determined by the heterologous RBP. In particular embodiments, the second foreign polynucleotide is heterologous to the first foreign polynucleotide. In some embodiments, the first and second polynucleotides are separate nucleic acid molecules. In other embodiments, the first and second polynucleotides are contained in one nucleic acid molecule. The following examples are intended to illustrate but not limit the invention.
The term “comprising”, which is used interchangeably with “including,” “containing,” or “characterized by,” is inclusive or open-ended language and does not exclude additional, unrecited elements or method steps. The phrase “consisting of” excludes any element, step, or ingredient not specified in the claim. The phrase “consisting essentially of” limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristics of the claimed invention. The present disclosure contemplates embodiments of the invention compositions and methods corresponding to the scope of each of these phrases. Thus, a composition or method comprising recited elements or steps contemplates particular embodiments in which the composition or method consists essentially of or consists of those elements or steps.
This example illustrates the identification of the genetic loci that encode a monocin within a strain of Listeria monocytogenes and a strain of Listeria innocua. Listeria monocytogenes strain ATCC 35152 and Listeria innocua strain ATCC 33090 were both reported to produce monocins. (Zink et al., 1994). These two strains were induced with mitomycin C, and the monocins were collected from the lysate by high speed centrifugation at 90,000×g. Bactericidal activity was tested by the spot method on a panel of Listeria species. The monocins from the two strains were found to have differing bactericidal spectra. Neither showed bactericidal activity against the same strain from which it was isolated. The entire purified monocin preparations were analyzed by mass spectrometry (MS) to identify in the sample proteins that had similarity to components of phage tail-like structures. Although strains 35152 and 33090 are not among those in which the genome sequences are known, numerous other Listeria genomes had been sequenced and were searchable. The most abundant protein in the preparation of monocin from strain 35152 corresponded to gene ImaA or antigen A encoded in numerous Listeria strains. Antigen A is a protein originally found to elicit an immune response in humans with Listeria infections (Gohmann et al., 1990; Schaferkordt et al., 1997). Prior to the instant invention it was not known that Antigen A was actually part of a monocin. The antigen A from strain 35152 showed identical peptide sequences to several homologues in known Listeria monocytogenes genomes; the sequenced genome of L. monocytogenes strain 1/2a F6854 was chosen as a reference, and the gene (ORF) numbering system of that strain was used for this work. The Antigen A corresponds to ORF 131 of strain 1/2a F6854. Several other peptide matches were noted from the MS analyses that corresponded to ORFs that are encoded in nearby regions of the genome including ORFs 130, 132, 135, 136, 138, and 140 (SEQ ID NOs: 7, 9, 12, 13, 15, 17, respectively). Several of these had sequence similarities to phage tail proteins (Table 1).
A close inspection of this genomic region revealed that ORFs 130-140 (SEQ ID NOs: 7-17, respectively) encoded the components of a contractile tail structure module (
Mass spectrometry data of the Listeria innocua 33090 lysate preparation gave similar results, with several peptides corresponding to a nearly identical gene cluster. L. monocytogenes strain 35152, which makes natural monocin 35152, was chosen as a source for nucleic acid encoding a scaffold for engineering novel monocins and novel expression cassettes for monocins.
This example illustrates the cloning of the genes for and expression of a monocin in a non-pathogenic producer cell.
The monocin gene cluster, from ORF 125 to ORF 142 (SEQ ID NOs: 2-19, respectively), was PCR-amplified from genomic DNA isolated from Listeria monocytogenes strain 35152 using primers oGL-054 and oGL-057 (Table 2). The PCR product and the vector DG630 (Gebhart et al., 2012) were both digested with restriction enzymes AscI and NotI and ligated together using T4 DNA ligase. This placed the monocin cluster between two flanking amyE sequences which allowed homologous recombination of the cluster into the amyE gene of B. subtilis. This plasmid construct was named pGL-031 (Table 3).
Bacillus Phyper-spank promoter and lacl
B.
subtilis/monocin 35152 (ORF 125-142).
B.
subtilis/monocin 35152 (ORF 125-140).
B.
subtilis/monocin 35152 (ORF 125-139),
B.
subtilis/Phyper-spank - monocin 35152
B.
subtilis/Phyper-spank - monocin 35152
B.
subtilis/Phyper-spank - monocin 35152
B.
subtilis/Phyper-spank - monocin 35152
B.
subtilis/Phyper-spank - monocin 35152
B.
subtilis/Phyper-spank - monocin 35152
pGL-031 was linearized by digestion with restriction enzyme SacII and transformed into the Bacillus subtilis strain, BDG9 (Gebhart et al., 2012). The transformation protocol was as follows: strain BDG9 was grown in MC medium (Gebhart et al., 2012) supplemented with final 3 mM MgSO4 for four hours at 37° C. The linearized pGL-031 DNA was mixed with 200 uL of the BDG9 cells culture and allowed to incubate for an additional 2 hours at 37° C. The transformation reactions were plated on LB plates supplemented with 5 μg/mL chloramphenicol and incubated overnight at 37° C. Chloramphenicol resistant colonies were selected and tested for monocin production. This monocin producer B. subtilis strain was termed sGL-064 (Table 4).
B. subtilis strain sGL-064 was cultured using the standard conditions and monocin production was induced with 5 mM hydrogen peroxide when the OD600 reached 0.2-0.4. The protein was harvested as described, and monocin bactericidal activity was assessed by spot assay. A spot assay is performed by adding 100 μl of target strain culture to 5 ml of TSB soft agar (0.5% agar), pouring the mixture onto a TSB agar plate, and allowing the soft agar to set. Five-fold serial dilutions of the protein preparation are made in TN50 buffer (10 mM TrisCl pH 7.5, 50 mM NaCl) and 3 μl of each dilution, including a sample of the undiluted protein preparation, are spotted onto the plate and allowed to dry. The plates are incubated overnight at 30° C. Killing is noted as zones of clearing on the bacterial lawn. Spot assays showed that the monocins produced by and purified from B. subtilis strains sGL-064, expressing 35152 ORF 125-ORF 142 (SEQ ID NOs: 2-19) had killing activity on L. monocytogenes strain 4b 23074.
This example illustrates the generation and expression of a construct containing a monocin gene cluster but lacking the genes responsible for lysis.
To remove the putative holin and lysin genes (ORFs 141-142, SEQ ID NOs: 18-19) from the monocin gene cluster, ORF 125 to ORF 140, SEQ ID NOs: 2-17, were PCR-amplified from L. monocytogenes 35152 genomic DNA using primers oGL-054 and oUC-001. The PCR product and the vector DG630 were both digested with restriction enzymes AscI and NotI and ligated together using T4 DNA ligase. This construct was named pUC-001. After integration into BDG9 as above, the resulting integrant strain was termed sUC-001. Spot assays showed that the monocins produced by and purified from B. subtilis strain sUC-001, expressing 35152 ORF 125-ORF 140 (SEQ ID NOs: 2-17), after induction as in Example 2 had bactericidal activity, as evidenced by the presence of spots on a lawn of the target, L. monocytogenes strain 4b 23074. Thus, by removing ORFs 141 and 142 (SEQ ID NOs: 18-19), the holin and lysin genes, a larger proportion of monocin remained in the cell pellet fraction rather than in the supernatant of the culture as compared to monocin production from B. subtilis producer strain sGL-064 (Table 5).
B.
subtilis producer
This example illustrated that changing (“RBP switching”) the natural RBP (ORF 0140, SEQ ID NO: 17) of monocin 35152 to that of monocin 33090 (SEQ ID NO: 27), an RBP heterologous to monocin 35152, changed the bactericidal spectrum of monocin 35152 to that of monocin 33090, now a non-natural monocin called monocin 35152-33090 (see
Based on both the position of ORF 140 (the last open reading frame of the structural genes and immediately preceding the lysis genes) and its sequence similarity to that of listeriophage tail fibers, it was speculated that this could be the RBP that determines the bactericidal spectrum of the monocin. To determine this, ORF 140 of 35152 (SEQ ID NO: 17) was replaced with that the equivalent ORF140 of Listeria innocua 33090 (SEQ ID NO: 27).
The L. monocytogenes 35152 gene cluster encoding from ORF 125 to ORF 139 (SEQ ID NOs: 2-16) was PCR-amplified using primers oGL-054 and oGL-075. The RBP gene from L. innocua strain 33090, ORF 174 (SEQ ID NO: 27), was PCR-amplified from genomic DNA using primers oGL-076 and oGL-083. These two PCR products were then used as template in an overlap PCR reaction to fuse ORF 125-ORF 139 (SEQ ID NOs: 2-16) from L. monocytogenes with ORF 174 (SEQ ID NO: 27) from L. innocua. For the overlap PCR, primers oGL-054 and oGL-077 were used. This PCR product was digested with AscI and NotI and ligated into vector DG630 which had also been digested with the same restriction enzymes. This construct was named pGL-033 (Table 3).
Integrants were made from BDG9 as above, resulting in strain sGL-068. A spot assay showed that monocin purified from the B. subtilis monocin producer strain sGL-068, expressing 35152 ORF 125-ORF 139 with 33090 ORF 174, has a different spectrum than the wild-type monocin 35152 produced by B. subtilis strain sGL-064, validating that changing the RBP gene altered the bactericidal spectrum of the monocin. The monocin with a heterologous RBP, a native ORF 174 from L. innocua 33090, instead of the natural RBP, ORF 140 from L. monocytogenes 35152, expressed with the 35152 monocin scaffold is termed monocin 35152-33090. Monocin 35152-33090 killed L. monocytogenes strain 19111, (
This example illustrated the generation of a polynucleotide containing a monocin gene cluster and operably linked to a heterologous inducible promoter, that is a promoter not found naturally in association with a monocin gene cluster.
To generate a version of DG630 with an inducible promoter regulating the expression of the monocin genes, the B. subtilis Phyper-spank (IPTG-inducible derivative of spac system SEQ ID NO: 28) (openwetware.org/images/a/al/Phs.doc) along with the gene lacI was PCR-amplified from plasmid DG481 (Gebhart et al., 2012) using primers oGL-084 and oGL-085. The PCR product was digested with AscI and NotI and ligated into vector DG630 which had also been digested with the same restriction enzymes. This construct was named pGL-034. The monocin gene cluster, from ORF 128 to ORF 140 (SEQ ID NOs: 5-17), was PCR-amplified using primers oGL-086 and oGL-087. The PCR product was then cloned into a HindIII-digested pGL-034 using Gibson assembly (New England Biolabs). The manufacturer's standard protocol was used. This construct was named pGL-036. After integrating into BDG9 the resulting B. subtilis strain was termed sGL-071.
Monocin was produced from sGL-071 upon addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) to the culture. Starter cultures of monocin producer cells were grown in 5 ml TSB media with 5 μg/ml chloramphenicol in a 15 ml culture tube at 28° C. with 250 RPM shaking and allowed to grow overnight (14-20 hours). This was then diluted 1/200 in 200 ml of TSB, 5 μg/ml chloramphenicol, at 28° C., with 250 RPM shaking for good aeration. When the OD600 reached 0.2, IPTG was added to a final concentration of 50 μM to induce monocin production. Incubation continued for an additional 14-20 hours. Cells were recovered by centrifugation at 6000×g for 20 min. The culture supernatant and the cells were both saved and processed since there was some “leakage” of monocins into the supernatant.
The culture supernatant was processed by ultracentrifugation at 90,000×g for 3 hours. These ultracentrifuged pellets were resuspended in 1 ml of TN50 buffer. The cells were resuspended in 10 ml of TN50 with 1 mg/ml lysozyme and 250 units of benzonase and then sonicated using a BioLogics Inc. model 300 V/T homogenizer with a microtip. Three 30 s pulses at half power was sufficient to release PTLB particles. The homogenized material was then centrifuged at 23,000×g to remove debris. Monocins were recovered from the supernatant by ultracentrifugation as described above for the culture supernatants. In an experiment in which no IPTG was added to the culture, no monocin activity was observed.
A construct was also made to drive the recombinant monocin 35152-33090 from this same heterologous, inducible promoter. The entire L. monocytogenes 35152 ORF 128-ORF 139 (SEQ ID NOs: 5-16) with the heterologous RBP from L. innocua 33090 ORF 174 (SEQ ID NO: 28) was PCR-amplified from plasmid pGL-033 using primers oGL-086 and oGL-089. The PCR product was then cloned into a HindIII-digested pGL-034 using Gibson assembly (per the instructions of the kit manufacturer, New England Biolabs). This construct was named pGL-038. The resulting BDG9 integrant was termed sGL-075.
This example illustrates the generation of a non-natural monocin having an altered bactericidal spectrum as the result of using an RBD from a phage to create a heterologous RBP.
As provided herein, it was found that it was possible to alter the bactericidal spectrum of a PTLB by making fusions with a portion of a natural RBP and a portion of an RBP of bacteriophage. The N-terminus of RBP protein was required for attachment of an RBP to the cognate baseplate of the monocin scaffold, while the C-terminal portion of the RBP, that is the RBD, interacted with a receptor on the target cell surface. Polynucleotide constructs were designed to fuse the portion of ORF 140 (SEQ ID NO: 17) encoding amino acid positions 1-40, for example, with the portion of the tail fiber ORF 2345 (SEQ ID NO: 21) of listeriophage A118 encoding amino acid positions 210-357. Four short ORFs (2344, 2343, 2342, and 2341, respectively SEQ ID NOs: 22-25) located immediately distal to the A118 tail fiber gene were also included.
The monocin 35152 gene cluster from ORF 128 through to the 5′ portion of ORF 140 was PCR-amplified using primers oGL-086 and oGL-112. The A118 phage tail fiber gene (SEQ ID NO: 21) was PCR-amplified from phage genomic DNA using primers oGL-120 and oGL-103. These two PCR products were cloned in a three-piece assembly with HindIII-digested pGL-034 using Gibson assembly. This construct was named pGL-045 and was comprised of a polynucleotide encoding amino acids 1-40 (BPAR) of SEQ ID NO: 17 and amino acid positions 210-357 (RBD) of SEQ ID NO: 21 plus SEQ ID NOs: 22-25. The resulting B. subtilis integrant was termed sGL-092. The entire gene cluster was under transcriptional control of the Phyper-spank promoter. The monocin with its heterologous RBP harvested from this monocin producer strain, sGL-092, had an altered bactericidal spectrum compared to that of the wild-type monocin 35152, demonstrating that an RBD of a phage tail fiber fused to an amino terminal portion, that is a BPAR, of a natural RBP, generated a monocin with a heterologous RBP and possessed an altered bactericidal spectrum determined by the heterologous RBD of the resulting heterologous RBP.
Monocins produced from sGL-092 had a bactericidal spectrum distinct from natural monocin 35152. (
This example discloses a means to increase the level of expression of a monocin by a monocin producer cell.
To improve the yield of the monocin 35152-A118, new monocin B. subtilis producer strains were generated in which the four short ORFs 2344, 2343, 2342, 2341 (SEQ ID NOs: 22-25) that were located just downstream of the A118 tail fiber gene of monocin 35152-A118 were removed one-by-one from the monocin 35152-A118 construct. It was speculated that one or more of these ORFs could affect the production of monocins. B. subtilis strain sGL-153 included only three of the downstream ORFs, 2344, 2343, and 2342, respectively SEQ ID NOs: 22-24. B. subtilis strain sGL-154 included only two of the downstream ORFs (2344 and 2343, SEQ ID NOs: 22-23). B. subtilis strain sGL-155 included only the first downstream ORF, 2344, SEQ ID NO: 22. These monocins with heterologous RBPs harvested from these B. subtilis monocin producer strains were spotted on a lawn of target strain L. monocytogenes 19111. The data showed that removal of downstream ORFs 2341 and 2342 (SEQ ID NOs: 24-25), but inclusion of ORFs 2343 and 2344 (SEQ ID NOs: 22-23) in the monocin 35152-A118 gene cluster greatly improved the activity yield.
This example demonstrates that monocins are bactericidal under cold temperatures.
To determine whether monocins can kill their target strains in the cold, a spot assay was conducted using monocin 35152 isolated from monocin producer B. subtilis strain sGL-071 and monocin 35152-A118 isolated from monocin producer B. subtilis strain sGL-154. Once a lawn of an appropriate target L. monocytogenes strain for each monocin was poured, the plates were chilled to 3-4° C. Monocin dilutions were made and also chilled to 3-4° C. prior to spotting. The chilled monocin dilutions were spotted onto the chilled agar plates. The plates were then incubated for 3 days at 3-4° C. The spot assays show that both monocin 35152 and monocin 35152-A118 can kill their respective target strains in the cold (
Many bacteriophage or PTLB RBPs require an accessory protein or chaperone for proper assembly of the tail fiber in order to get optimal active bacteriocin. This example demonstrates that monocin 35152-A118 requires the phage A118 gene 2344 product for this purpose.
Just downstream of the gene encoding tail fiber RBP of bacteriophage A118 are three small open reading frames, ORFs 2344, 2343, and 2342, followed by the genes encoding holin (SEQ ID NO.:025) and lysin. To determine whether any of these ORFs encoded necessary tail fiber assembly proteins, four 35152-A118 monocin expression constructs were generated, using the same methodology as described in example 6, as set forth below.
Briefly, the 35152 monocin gene cluster, ORF 0128 through to the 5′ portion of ORF 0140, was PCR-amplified using primers oGL-086 and oGL-112. The A118 phage tail fiber gene was PCR-amplified from phage genomic DNA using forward primer oGL-120 and reverse primer oGL-162, oGL-163, oGL-164 or oGL-165 to include three, two, one, or no downstream chaperone(s). The monocin PCR product and each of the A118 PCR products were cloned in a three piece Gibson assembly into HindIII-digested pGL-034. These constructs were named pGL-075, pGL-076, pGL-077, and pGL-078. The plasmids were integrated into strain A8. The resulting integrants were named sGL-364, sGL-158, sGL-365, and sGL-366, respectively.
One construct included all three putative assembly proteins encoded by ORFs 2344, 2343, and 2342; SEQ ID NOs: 024, 023, 022, respectively), another construct included just 2344 and 2343, another construct included just 2344, and a final construct had none. These were each separately expressed in Bacillus subtilis and the resulting monocins were assayed for activity on strain 19111. The construct that had no putative tail fiber assembly proteins gave no active monocin particles. The construct that included expression of ORF 2344 produced robust activity. The construct that included 2344 and 2343 gave monocin yields and activity nearly identical to the construct that had just 2344. The construct that included all three putative tail fiber assembly proteins actually yielded slightly less monocin activity. See
To further improve monocin yields, a modified B. subtilis production strain deleted of prophage genes, sporulation functions, and flagella synthesis, was constructed. B. subtilis strain Δ6 was used, which had a series of prophage element deletions including prophage 1, prophage 3, SPβ, PBSX, and Skin (Westers et al). Strain Δ6 was further modified by deleting flagella production (Δhag) and sporulation (Δspollga) to generate strain Δ8. The M35152 gene cluster, minus holin/lysin, was transformed/integrated into Δ8, regulated with Phyper-spank upstream of ORF 0128, as in sGL-071. The resulting strain sGL-157 (M35152) had improved monocin production (typically 5-10 fold) over BDG9-based counterpart. See
The methods used to produce this strain are detailed as follows. Bacillus subtilis knockouts were made following the methods described in Tanaka et al. (Tanaka K, Henry C S, Zinner J F, Jolivet E, Cohoon M P, Xia F, Bidnenko V, Ehrlich S D, Stevens R L, Noirot P. 2013. Building the repertoire of dispensable chromosome regions in Bacillus subtilis entails major refinement of cognate large-scale metabolic model. Nucleic Acids Res. 41:687-699). Strain Δ6 was described by Westers et al. (Westers H, Dorenbos R, van Dijl J M, Kabel J, Flanagan T, Devine K M, Jude F, Seror S J, Beekman A C, Darmon E, Eschevins C, de Jong A, Bron S, Kuipers O P, Albertini A M, Antelmann H, Hecker M, Zamboni N, Sauer U, Bruand C, Ehrlich D S, Alonso J C, Salas M, Quax W J. 2003. Genome engineering reveals large dispensable regions in Bacillus subtilis. Mol Biol Evol 20:2076-2090) and is a prophage deletion strain. In order to manipulate strain Δ6 further, the cat gene, which was a remnant from the original pks operon knockout, was removed. First the upp::kan marker was amplified from Bacillus subtilis strain TF8A λPr-neo:Δupp with primers oDG1013 and oDG1014. The PCR product was cloned into pETcocol linearized with NotI. This plasmid was then linearized with Spe1 and transformed into Δ6 and selected for kanr. This strain was termed BDG243. To delete the cat gene, the phleomycin cassette was amplified from pUC18 phleo cassette (Tanaka et al.) in a sewing PCR reaction with two flanking regions from Δ6 using the primers oDG1001 and oDG1002, (left flank) oDG999 and oDG1000 (phleomycin cassette), oDG1003 and oDG1004 (right flank) and the three pieces combined by amplification with the two outside primers oDG1001 and oDG1004. This PCR product was transformed into BDG243 and selected on phleomycin plates followed by screening for kanamycin sensitivity. This strain is designated BDG247. The phleomycin marker was deleted by growing BDG247 in LB without selection for 4 hours, plated on kanamycin, and colonies picked and screened for phleomycin sensitivity. This strain, BDG252, was a markerless knock-out strain, useful for making further modifications. To delete hag, the 5′ flanking region of hag was amplified with primers oDG1019 and oDG 1020, the 3′ flank amplified with oDG1021 and oDG1022, and the pleomycin cassette amplified with oDG999 and oDG1000. The three PCR products were combined and a sewing reaction performed with oDG1019 and oDG1022. This product was transformed into BDG252, selected on phleomycin, and then screened for kanamycin sensitivity to create BDG253. The phleomycin marker was again deleted by growing BDG253 in LB without selection for 4 hours, plating on kanamycin, and screening colonies for phleomycin sensitivity to create strain BDG255. To delete spoIIga, the 5′ flank was amplified with primers oDG1023 and oDG1024, the 3′ flank amplified with oDG1025 and oDG1026, and the phleomycin cassette amplified with oDG999 and oDG1000. The three products were combined in a sewing reaction using primers oDG1023 and oDG1026. After transformation, selection on phleomycin, and screening for phleomycin resistance, the resulting strain was named BDG256. The phleomycin marker was deleted, again by growing BDG256 in LB without selection for 4 hours, plating on kanamycin, and screening colonies for phleomycin sensitivity to create strain BDG257, also known as the Δ8 strain.
Most human illness caused by Listeria in North America is caused by two predominant serotypes, 1/2a and 4b (Nelson, K. E., D. E. Fouts, E. F. Mongodin, J. Ravel, R. T. DeBoy, J. F. Kolonay, D. A. Rasko, S. V. Angiuoli, S. R. Gill, I. T. Paulsen, J. Peterson, O. White, W. C. Nelson, W. Nierman, M. J. Beanan, L. M. Brinkac, S. C. Daugherty, R. J. Dodson, A. S. Durkin, R. Madupu, D. H. Haft, J. Selengut, S. Van Aken, H. Khouri, N. Fedorova, H. Forberger, B. Tran, S. Kathariou, L. D. Wonderling, G. A. Uhlich, D. O. Bayles, J. B. Luchansky, and C. M. Fraser. 2004. Whole genome comparisons of serotype 4b and 1/2a strains of the food-borne pathogen Listeria monocytogenes reveal new insights into the core genome components of this species. Nucleic Acids Res. 32:2386-2395. Accordingly, the bactericidal activity of monocins 35152 and 35152-Δ118 were tested against a panel of independent Listeria isolates. See Table 6. Monocin 35152 killed 4b strains, whereas monocin 35152-Δ118 killed 1/2a strains. Therefore, a biocontrol agent that includes monocins 35152 and 35152-Δ118 may be used to kill these foodborne pathogenic strains.
All high molecular weight bacteriocins described to date have been related to either contractile Myoviridae-like structures (R-type) or Lambda-like tail Siphoviridae structures (traditional F-type). Monocins were shown to be F-type bacteriocin based on a lack of a contractile sheath protein and electron microscopy. However, as shown herein, monocins were determined to be closely and specifically related to the tail structure of phage Δ118, a TP901-1-like phage (Cambillau, 2015). Comparison of a monocin major tail protein (SEQ ID NO.: 8) to those of TP901-1-like phages (SEQ ID NOS.: 30, 31) including Δ118 (SEQ ID NO.: 32), and comparison of monocin tape measure protein and baseplate proteins (respectively SEQ ID NOs.: 11, 12, 13) to those respective proteins of phage Δ118 (SEQ ID NOs.: 33, 34 and 35), indicated that monocins as described herein were structurally TP901-1-like. In addition, three monocin regulatory proteins (SEQ ID NOs.: 3, 5 and 6) were shown to have Δ118 homologues (SEQ ID NOs.: 36, 37, 38). A comparison of protein sequences encoded by the monocin gene cluster to those encoded by the Δ118 genome is shown in
TP901-1-like phages have a distinct baseplate structure wherein the receptor binding protein (RBP), a homotrimeric protein, is arranged in six groups with three “tripods” each (see Bebeacua C, Tremblay D, Farenc C, Chapot-Chartier M P, Sadovskaya I, van Heel M, Veesler D, Molineau S, Cambillau C. 2013. Structure, adsorption to host, and infection mechanism of virulent lactococcal phage p2. J Virol 87:12302-12312; Collins B, Bebeacua C, Mahony J, Blangy S, Douillard F P, Veesler D, Cambillau C, van Sinderen D. 2013, Structure and functional analysis of the host recognition device of lactococcal phage tuc2009. J Virol 87:8429-8440; and Cambillau C, 2015, Bacteriophage module reshuffling results in adaptive host range as exemplified by the baseplate model of listerial phage A118. Virology 484: 86-92).
This results in a total of 54 RBPs per phage particle (3×3×6). R- and F-type bacteriocins are known to possess just six copies of single homotrimers (18 total copies). This is the first example of a TP901-1-related structure capable of functioning as a high molecular weight bacteriocin.
All references cited herein, including patents, patent applications, and publications, are hereby incorporated by reference in their entireties, whether previously specifically incorporated or not.
Having now fully described this invention, it will be appreciated by those skilled in the art that the same can be performed within a wide range of equivalent parameters, concentrations, and conditions without departing from the spirit and scope of the invention and without undue experimentation.
While this invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications. This application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth.
Although the invention has been described with reference to the above example, it will be understood that modifications and variations are encompassed within the spirit and scope of the invention. Accordingly, the invention is limited only by the following claims.
This application claims the benefit of United States Provisional Application Nos. 62/076,691, filed Nov. 7, 2014, and 62/245,493, filed Oct. 23, 2015, the contents of all of which are incorporated herein by reference in their entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 20060078901 | Buchrieser | Apr 2006 | A1 |
| Number | Date | Country |
|---|---|---|
| WO-0177335 | Oct 2001 | WO |
| Entry |
|---|
| Zink et al. Supplementary Listeria-typing with defective Listeria phage particles (monocins). Letters in Applied Microbiology, vol. 19, pp. 99-101, 1994. (Year: 1994). |
| Zink et al. Characterization of cryptic prophages (monocins) in Listeria and sequence analysis of holin/endolysin gene. Microbiology, vol. 141, pp. 2577-2584, 1995. (Year: 1995). |
| Williams et al. Retargeting R-type pyocins to generate novel bactericidal protein complexes. Applied and Environmental Microbiology, vol. 74, No. 12, pp. 3868-3876, Jun. 2008, including pp. 1/4-4/4 of Supplemental Material. (Year: 2008). |
| Ghequire et al. The tailocin tail: Peeling off phage tails. Trends in Microbiology, vol. 23, No. 10, pp. 587-590, Oct. 2015. (Year: 2015). |
| Merrikin et al. Use of pyocin 78-C2 in the treatment of APseudomonas aeruginosa infection in mice. Applied Microbiology, vol. 23, No. 1, pp. 164-165, Jan. 1972. (Year: 1972). |
| Haas et al. Protective effect of pyocin against lethal Pseudomonas aeruginosa infections in mice. The Journal of Infectious Diseases, vol. 129, No. 4, pp. 470-472, Apr. 1974. (Year: 1974). |
| Williams. Treatment of Pseudomonas aeruginosa infections with pyocines. Journal of Medical Microbiology, vol. 9, pp. 153-161, 1976. (Year: 1976). |
| Payne et al. Phage therapy: The peculiar kinetics of self-replicating pharmaceuticals. Clinical Pharmacology & Therapeutics, vol. 68, No. 3, pp. 225-230, Sep. 2000. (Year: 2000). |
| Skurnik et al. Phage therapy: Facts and fiction. International Journal of Medical Microbiology, vol. 296, pp. 5-14, Feb. 2006. (Year: 2006). |
| Tsonos et al. A cocktail of in vitro efficient phages is not a guarantee for in vivo therapeutic results against avian colibacillosis. Veterinary Microbiology, vol. 171, pp. 470-479, Jul. 2014, Epub Nov. 4, 2013. (Year: 2013). |
| Scholl et al. An engineered R-type pyocin is a highly specific and sensitive bactericidal agent for the good-borne pathogen Escherichia coli O154:57. Antimicrobial Agents and Chemotherapy, vol. 53, No. 7, pp. 3074-3080, Jul. 2009, including p. 1/4-4/4 of Supplemental Tables. (Year: 2009). |
| GenBank Accession No. EAL07464.1, publicly available May 2004, printed as p. 1/1. (Year: 2004). |
| Number | Date | Country | |
|---|---|---|---|
| 20160130309 A1 | May 2016 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62076691 | Nov 2014 | US | |
| 62245493 | Oct 2015 | US |
